Exchange: NASDAQ·Updated 07:56 PM EDT

CMPS News

News
all
press releases
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate...
Business Wire
More News
Compass Pathways Launches Change the Tune in TRD in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of...
Business Wire
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training PR Newswire NEW YORK, Sept. 10, 2026 New certificate program will prepare clinicians to support patients receiving COMP360...
PR Newswire
Compass Pathways to Participate in Investor Conferences the Week of September 14th
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global...
Business Wire
Compass Pathways' Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.read more...
Benzinga
CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch
Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks.
Stocktwits
Compass Pathways New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for...
Business Wire
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027.
Stocktwits
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress 2026, taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in...
Business Wire
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees...
Business Wire

Advertisement|Remove ads.